Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers

Omega 3 Fatty Acid Trial

NCT00586222
Conditions
Omega-3 Fatty Acids, Pediatric Bipolar Disorder, Adolescent Bipolar Disorder, Magnetic Resonance Spectroscopy Imaging
Interventions
Omega-3 Fatty Acid, Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Depression, Bipolar I Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
10 Years to 17 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
69
States / cities
Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more
Completed Phase 2 Interventional Results available

Lamotrigine Monotherapy in Pediatric Bipolar Disorder

NCT00176228
Conditions
Bipolar Disorder
Interventions
Lamotrigine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
10 Years to 20 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Bipolar I Disorder
Interventions
Extended-Release Carbamazepine
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 22 more
Conditions
Bipolar Disorder, Pediatric Bipolar Disorder, Childhood-onset Bipolar Disorder
Interventions
COGFLEX-skill building levels, COGFLEX-control condition
Behavioral
Lead sponsor
Bradley Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
East Providence, Rhode Island
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Washington D.C., District of Columbia • South Chicago Heights, Illinois • Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, Kansas + 7 more
Completed Phase 3 Interventional Results available

Pediatric Bipolar Depression

NCT00811473
Conditions
Bipolar Depression
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Conditions
Bipolar Disorder
Interventions
lamictal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Dothan, Alabama • Scottsdale, Arizona • San Diego, California + 39 more
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
56
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
Completed Phase 4 Interventional Results available

Ziprasidone in Pediatric Bipolar Disorder

NCT00622739
Conditions
Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

The Family VOICE Study

NCT01804582
Conditions
Autism, Aggression, Bipolar Disorder, Psychotic Disorders
Interventions
Family Navigator consultation
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Years to 15 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Completed No phase listed Observational

Pediatric Bipolar Registry

NCT02360267
Conditions
Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Lurasidone Pediatric Bipolar Study

NCT02046369
Conditions
Bipolar I Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Dothan, Alabama • Culver City, California • Hartford, Connecticut + 27 more
Conditions
Bipolar Disorder
Interventions
Ketamine hydrochloride injection, Flat tonic water (e.g., Canada Dry Tonic Water)
Drug
Lead sponsor
Juvenile Bipolar Research Foundation
Other
Eligibility
6 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Not Predetermined, Connecticut • Maplewood, New Jersey • Not Predetermined, New Jersey + 1 more
Completed Phase 4 Interventional Results available

Inositol and Omega-3 Fatty Acids in Pediatric Mania

NCT01396486
Conditions
Pediatric Bipolar Spectrum Disorders
Interventions
Omega-3, Inositol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pediatric Bipolar Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
4 Years to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
OLZ/SAM
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Dothan, Alabama • Little Rock, Arkansas • Stanford, California + 11 more